Sudarshan Pharma Industries (543828) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
30 Jan, 2026Executive summary
Unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December 2025 were approved and reviewed by the Board and auditors, with no material misstatements noted.
Financial highlights
Standalone revenue from operations for Q3 FY26 was ₹15,837.13 lakhs, with net profit at ₹430.54 lakhs, up from ₹275.82 lakhs in Q3 FY25.
Consolidated revenue for Q3 FY26 was ₹16,800.66 lakhs, with net profit at ₹414.85 lakhs, compared to ₹288.20 lakhs in Q3 FY25.
Nine-month standalone net profit reached ₹1,243.89 lakhs, and consolidated net profit was ₹1,197.93 lakhs.
Basic and diluted EPS for Q3 FY26 stood at ₹0.18 (standalone) and ₹0.18 (consolidated).
Outlook and guidance
The company voluntarily adopted Ind AS from April 1, 2025, with restated prior period figures for comparability.
Latest events from Sudarshan Pharma Industries
- USFDA-approved API facility with global clients, robust operations, and top-tier compliance.543828
Investor presentation - Year-over-year profit and revenue growth, cost rationalization, FCCB funding, and US expansion.543828Q1 26/27
- Strong revenue and profit growth, strategic expansion, and renewed FCCB fundraising drive.543828Q4 25/26
- Revenue, assets, and international presence expanded, with major fundraising and acquisitions approved.543828Q2 2026
- Q1 FY26 delivered strong revenue growth and a return to profit, aided by strategic acquisitions.543828Q1 25/26
- Slight profit dip, major expansion moves, and a significant litigation win mark H1 FY25.543828Q2 24/25
- FY25 saw robust growth, acquisitions, and exceptional items impact at Sudarshan Pharma.543828Q4 24/25